logo

NEO

Neogenomics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

NEO fundamentals

Neogenomics (NEO) released its earnings on Oct 28, 2025: revenue was 187.80M (YoY +11.91%), beat estimates; EPS was 0.03 (YoY -40.00%), beat estimates.
Revenue / YoY
187.80M
+11.91%
EPS / YoY
0.03
-40.00%
Report date
Oct 28, 2025
NEO Earnings Call Summary for Q3,2025

Key Takeaways:

  • Revenue Momentum: 12% YoY growth driven by 24% NGS expansion and 15% clinical volume growth.
  • MRD Breakthrough: RaDaR ST launch in Q1 2026 targets $30B MRD market, with pharma bookings starting Q4 2025.
  • Operational Efficiency: LIMS consolidation and sales force expansion to drive 2026+ margin improvement.
  • Strategic Focus: Community oncology consolidation (80%+ cancer care) and AI-driven MRD innovation.
EPS
Revenue

Revenue & Expenses

NEO has released its 2025 Q3 earnings report, with revenue of 187.80M, reflecting a YoY change of 11.90%, and net profit of -27.13M, showing a YoY change of -53.28%. The Sankey diagram below clearly presents NEO's revenue sources and cost distribution.

Key Indicators

Neogenomics (NEO) key financial stats and ratios, covering profitability, financial health, and leverage.
Neogenomics (NEO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Neogenomics (NEO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Neogenomics (NEO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Neogenomics (NEO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Neogenomics (NEO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield